Rémi Droller is a venture capital investor at Kurma Partners who combines deep scientific training with over 25 years of biotech investing experience, and he typically works 1-3 years with academic teams through the Argobio start-up studio before a company even exists, co-designing scientific plans and derisking experiments so founders encounter him as a co-builder rather than a late-arriving VC. He repeatedly engineers cross-border combinations of European science and teams to build assets that can be acquired at unusually early stages, and has a track record of turning repeat entrepreneurs and small seeds into billion-dollar outcomes like Amolyt Pharma's sale to AstraZeneca for over $1 billion.
About their Fund
Kurma Partners operates two specialized healthcare franchises under one roof—Kurma Biofund for therapeutics and biotech company creation from academic labs, and Kurma Diagnostics for diagnostics and digital health—while offering a full innovation-to-growth continuum through its dedicated Growth Opportunities Fund that continues financing promising portfolio companies into scale-up rounds. The firm has built a systematic company-creation engine with major European research institutes like Institut Pasteur and VIB, spinning out academic research into venture-backed companies and providing portfolio companies with operational support through strategic partnerships like its alliance with Samsung Biologics for development and manufacturing capabilities.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































